Suppr超能文献

亚临床甲状腺功能减退患者的神经心理功能和症状以及甲状腺素治疗的效果。

Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment.

作者信息

Jorde Rolf, Waterloo Knut, Storhaug Hilde, Nyrnes Audhild, Sundsfjord Johan, Jenssen Trond Geir

机构信息

Institute of Clinical Medicine (R.J., K.W.), University of Tromsø, 9037 Tromsø, Norway.

出版信息

J Clin Endocrinol Metab. 2006 Jan;91(1):145-53. doi: 10.1210/jc.2005-1775. Epub 2005 Nov 1.

Abstract

OBJECTIVE

Our objective was to examine the relation between neuropsychological function and subclinical hypothyroidism (SHT), defined as serum TSH of 3.5-10.0 mIU/liter and normal serum free T4 and free T3 levels, and to study the effect of T4 supplementation.

SUBJECTS

A total of 89 subjects (45 males) with SHT and 154 control subjects (72 males) were recruited from a general health survey (the fifth Tromsø study). Sixty-nine of those with SHT were included in a placebo-controlled, double-blind intervention study with T4 medication for 1 yr.

MAIN OUTCOME MEASURES

We used fourteen tests of cognitive function, Beck Depression Inventory, General Health Questionnaire, and a questionnaire on hypothyroid symptoms.

RESULTS

The mean +/- sd serum TSH in the SHT and control group were 5.57 +/- 1.68 and 1.79 +/- 0.69 mIU/liter, respectively. There were no significant differences in cognitive function and hypothyroid symptoms between the two groups, but those with SHT scored significantly better than the controls on the GHQ-30. At the end of the intervention study, serum TSH in the T4 group (n = 36) and the placebo group (n = 33) were 1.52 +/- 1.51 and 5.42 +/- 1.96 mIU/liter, respectively. T4 substitution had no effect on any of the parameters measured.

CONCLUSION

In subjects with SHT where the serum TSH level is in the 3.5-10.0 mIU/liter range, there is no neuropsychological dysfunction, and compared with healthy controls, there is no difference in symptoms related to hypothyroidism.

摘要

目的

我们的目的是研究神经心理功能与亚临床甲状腺功能减退(SHT,定义为血清促甲状腺激素(TSH)为3.5 - 10.0 mIU/升且血清游离T4和游离T3水平正常)之间的关系,并研究补充T4的效果。

受试者

从一项普通健康调查(特罗姆瑟第五次研究)中招募了总共89名患有SHT的受试者(45名男性)和154名对照受试者(72名男性)。其中69名患有SHT的受试者被纳入一项为期1年的T4药物安慰剂对照双盲干预研究。

主要观察指标

我们使用了14项认知功能测试、贝克抑郁量表、一般健康问卷以及一份关于甲状腺功能减退症状的问卷。

结果

SHT组和对照组的平均±标准差血清TSH分别为5.57±1.68和1.79±0.69 mIU/升。两组在认知功能和甲状腺功能减退症状方面无显著差异,但SHT组在GHQ - 30上的得分显著高于对照组。在干预研究结束时,T4组(n = 36)和安慰剂组(n = 33)的血清TSH分别为1.52±1.51和5.42±1.96 mIU/升。T4替代对所测量的任何参数均无影响。

结论

在血清TSH水平处于3.5 - 10.0 mIU/升范围内的SHT受试者中,不存在神经心理功能障碍,并且与健康对照组相比,甲状腺功能减退相关症状没有差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验